FTSE MIB
34.428,86 +65,11 (+0,19%) Dow Jones
38.503,69 +263,71 (+0,69%) Nasdaq
15.696,64 +245,33 (+1,59%) Nikkei 225
38.460,08 +907,92 (+2,42%) Petrolio
83,38 +0,02 (+0,02%) Bitcoin EUR
62.553,08 +463,48 (+0,75%)
Benitec Biopharma Inc. (BNTC)
Dopo ore:
| Chiusura precedente | 6,72 |
| Aperto | 6,57 |
| Denaro | 4,93 x 200 |
| Lettera | 8,71 x 200 |
| Min-Max giorno | 6,57 - 7,04 |
| Intervallo di 52 settimane | 1,86 - 9,01 |
| Volume | |
| Media Volume | 81.583 |
| Capitalizzazione | 57,223M |
| Beta (5 anni mensile) | 1,02 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -236,13 |
| Prossima data utili | 13 mag 2024 - 17 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 16,00 |
GlobeNewswireBenitec Biopharma Releases Full Year 2023 Financial Results and Provides Operational Update
Received FDA Clearance of the Investigational New Drug (IND) application for BB-301 for the Treatment of Oculopharyngeal Muscular Dystrophy (OPMD)-Related Dysphagia 15 subjects enrolled in the OPMD Natural History Study, with multiple subjects entering the eligibility period this year for entry into the BB-301 Phase 1b/2a Clinical Treatment Study Successful Closing of a $30.9 M Public Offering HAYWARD, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or
- GlobeNewswire
Benitec Biopharma Inc. Announces Closing of $30 Million Underwritten Public Offering
HAYWARD, Calif., Aug. 11, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (Nasdaq: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference ("ddRNAi") “Silence and Replace” platform, today announced it closed its previously announced underwritten public offering of 15,544,041 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof)
- GlobeNewswire
Benitec Biopharma Inc. Announces Pricing of $30 Million Underwritten Public Offering
HAYWARD, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (Nasdaq: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference ("ddRNAi") “Silence and Replace” platform, today announced the pricing of its underwritten public offering of 15,544,041 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and accompanyin
